Clinical trials: Non-small Cell Lung Cancer (NSCLC) Stage IV
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Non Small Cell Lung Cancer
EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)
Primary trial objective in this single arm trial is to assess the safety and tolerability of Selectikine (EMD 521873) given in combination with and local tumor irradiation and to determine whether the maximum tolerated dose (MTD)…
- Trial name
- NCT00879866
- Testing
- EMD 521873
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer, Radiation Toxicity
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00955942
- Testing
- flaxseed
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance
This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients…
- Trial name
- NCT04316351
- Testing
- Toripalimab + Pemetrexed + Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous…
- Trial name
- CheckMate 169 (NCT02475382)
- Testing
- Nivolumab
- Where
- 50 sites in Brazil, Canada
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
NSCLC Stage IV, EGFR T790M-negative
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.
- Conditions
- NSCLC Stage IV, EGFR T790M-negative, Anlotinib, JS001
- Trial name
- NCT04116918
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Baodong Qin
Lung Cancer
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268489
- Testing
- bevacizumab, pemetrexed disodium
- Where
- 248 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cachexia, Fatigue
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
This randomized clinical trial studies pulmonary rehabilitation in improving lung function in patients with locally advanced non-small cell lung cancer undergoing chemoradiation.
- Conditions
- Cachexia, Fatigue, Pulmonary Complications, Radiation Toxicity
- Trial name
- NCT02017925
- Testing
- exercise intervention, pulmonary complications management/prevention, quality-of-life assessment
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Lung Cancer, Metastatic Cancer
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01302808
- Testing
- Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon…
- Trial name
- NCT00064350
- Testing
- Sorafenib
- Where
- 141 sites in United States
- Volunteers
- 342 people
- Sponsor
- Eastern Cooperative Oncology Group
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
NSCLC (Non-small Cell Lung Carcinoma)
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is…
- Trial name
- NCT02119650
- Testing
- Ruxolitinib, Pemetrexed, Cisplatin
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- Incyte Corporation
Melanoma Stage III, Melanoma Stage IV
Appropriate Dosing to Optimise Personalised Cancer Treatments
This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Ovarian Cancer, Renal Cancer Stage III
- Trial name
- ADOPT (NCT04154163)
- Testing
- Dried blood Spot (DBS), Venous blood sampling
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Dundee
Lung Cancer, Metastatic Cancer
QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function (the ability to think, learn, remember, and judge) in patients with non-small cell lung cancer and brain metastases.
- Trial name
- NCT00385398
- Testing
- erlotinib hydrochloride, temozolomide, stereotactic radiosurgery
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Conditions
- Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
- Trial name
- NCT03532698
- Testing
- Aspirin, Osimertinib
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-small Cell Lung Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
- Trial name
- NSCLC (NCT01234038)
- Testing
- ISIS EIF4E Rx, Paclitaxel, Carboplatin
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 116 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Lung Neoplasm, Carcinoma, Bronchogenic
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
In this Phase II clinical trial the investigators will use four human non-small cell lung cancer cell lines that have been previously established in tissue culture laboratory.
- Trial name
- NCT01058785
- Testing
- Lucanix
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- NovaRx Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.